XML 54 R44.htm IDEA: XBRL DOCUMENT v3.22.0.1
Collaboration Agreements, License Agreement and Revenues - Summary of License Revenue and Development Revenue Recognized under Agreement (Detail) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue $ 235,309 $ 176,319 $ 256,577
License Revenue [Member]      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue 116,434 14,323 177,086
Development Revenue [Member]      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue 70,275 80,592 114,115
Astellas Agreement [Member] | License Revenue [Member] | Japan [Member]      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue 0 14,323 11,935
Astellas Agreement [Member] | License Revenue [Member] | Europe [Member]      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue 108,434 0 117,470
Astellas Agreement [Member] | Development Revenue [Member] | Japan [Member]      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue 248 1,220 1,222
Astellas Agreement [Member] | Development Revenue [Member] | Europe [Member]      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue 21,679 17,954 28,172
AstraZeneca Agreements [Member] | China [Member]      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue 0 (90) 90
AstraZeneca Agreements [Member] | License Revenue [Member] | U.S./RoW and China [Member]      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue 0 0 47,681
AstraZeneca Agreements [Member] | Development Revenue [Member] | U.S./RoW and China [Member]      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue $ 48,345 $ 61,508 $ 84,629